U.S. markets close in 3 hours 33 minutes

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7800-0.0800 (-1.65%)
As of 12:26PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.8600
Open4.8500
Bid4.7700 x 1200
Ask4.8400 x 800
Day's Range4.7501 - 5.0500
52 Week Range4.2800 - 8.2400
Volume64,675
Avg. Volume297,224
Market Cap23.638M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies
    Benzinga

    Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies

    Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's objective was to assess neurotoxicity resulting from a long residence time of a local anesthetic in proximity to the sciatic nerve in rabbits. The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs. Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage. Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaJohnson & Johnson Becomes Third Company To Expand COVID-19 Vaccine Study To AdolescentsMolecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Virpax Announces Results of Probudur(TM) in Animal Study
    ACCESSWIRE

    Virpax Announces Results of Probudur(TM) in Animal Study

    BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of a sciatic nerve preclinical study in rabbits designed to evaluate nerve damage from locally injected Probudur™, Virpax's liposomal bupivacaine product candidate.

  • Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Probudur(TM) for Postoperative Pain
    ACCESSWIRE

    Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Probudur(TM) for Postoperative Pain

    BERWYN, PA / ACCESSWIRE / March 22, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that preclinical studies of Probudur™, a proprietary patented injectable, long-acting "local anesthetic" Liposomal (Hydro) Gel Technology for postoperative pain management, have been initiated under an agreement with Charles River Laboratories.